Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS - PharmiWeb.com (press release)

Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS PharmiWeb.com (press release) Basel, August 25, 2016 - Novartis today announced the Phase III EXPAND study, evaluating the efficacy and safety of oral, once-daily, BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), met its primary endpoint of a reduction in the ... and more »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNGOFTxZ14PIQz4ScEySsFoyibCLQA&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779188673549&ei=kJ2-V6AfwYveAbi4osgC&url=http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID%3D179845
via IFTTT